Back to top
more

Autolus Therapeutics (AUTL)

(Delayed Data from NSDQ)

$4.02 USD

4.02
528,756

+0.10 (2.55%)

Updated May 28, 2024 04:00 PM ET

After-Market: $4.02 0.00 (0.00%) 6:12 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.08%
2Buy17.91%
3Hold9.44%
4Sell5.10%
5Strong Sell2.55%
S&P50011.04%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

F Value F Growth D Momentum F VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 36% (89 out of 250)

Industry: Medical - Biomedical and Genetics

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Brokerage Reports

Research for AUTL

The Zacks Equity Research reports, or ZER for short, are our in-house, independently produced research reports.

The ever popular one-page Snapshot reports are generated for virtually every single Zacks Ranked stock. It's packed with all of the company's key stats and salient decision making information. Including the Zacks Rank, Zacks Industry Rank, Style Scores, the Price, Consensus & Surprise chart, graphical estimate analysis and how a stocks stacks up to its peers.

The detailed multi-page Analyst report does an even deeper dive on the company's vital statistics. In addition to all of the proprietary analysis in the Snapshot, the report also visually displays the four components of the Zacks Rank (Agreement, Magnitude, Upside and Surprise); provides a comprehensive overview of the company business drivers, complete with earnings and sales charts; a recap of their last earnings report; and a bulleted list of reasons to buy or sell the stock. It also includes an industry comparison table to see how your stock compares to its expanded industry, and the S&P 500.

Researching stocks has never been so easy or insightful as with the ZER Analyst and Snapshot reports.

Learn more about Zacks Equity Research reports

See more Zacks Equity Research reports

 

0 items in cart

Autolus Therapeutics PLC Sponsored ADR [AUTL]

Reports for Purchase

Showing records 21 - 40 ( 41 total )

Company: Autolus Therapeutics PLC Sponsored ADR

Industry: Medical - Biomedical and Genetics

Record: 21

03/04/2020

Company Report

Pages: 12

Lots to Look Forward to Heading Into 2Q20 and Beyond

Provider: H.C. Wainwright & Co., Inc.

Analyst: CHATTOPADHYAY D

Price: 25.00

Research Provided by a Third Party

Company: Autolus Therapeutics PLC Sponsored ADR

Industry: Medical - Biomedical and Genetics

Record: 22

03/02/2020

Industry Report

Pages: 7

From TINA to Cash Is King and Other Musings

Provider: H.C. Wainwright & Co., Inc.

Analyst: Research Department

Price: 25.00

Research Provided by a Third Party

Company: Autolus Therapeutics PLC Sponsored ADR

Industry: Medical - Biomedical and Genetics

Record: 23

02/18/2020

Company Report

Pages: 12

The Time to Get Long Is Now

Provider: H.C. Wainwright & Co., Inc.

Analyst: CHATTOPADHYAY D

Price: 25.00

Research Provided by a Third Party

Company: Autolus Therapeutics PLC Sponsored ADR

Industry: Medical - Biomedical and Genetics

Record: 24

02/14/2020

Industry Report

Pages: 7

Runners up Is the New Killing It, and Other Tidbits

Provider: H.C. Wainwright & Co., Inc.

Analyst: CHATTOPADHYAY D

Price: 25.00

Research Provided by a Third Party

Company: Autolus Therapeutics PLC Sponsored ADR

Industry: Medical - Biomedical and Genetics

Record: 25

02/07/2020

Daily Note

Pages: 9

Let?s Caucus, or Never Again; In an Otherwise Ho-Hum Earnings Week

Provider: H.C. Wainwright & Co., Inc.

Analyst: CHATTOPADHYAY D

Price: 25.00

Research Provided by a Third Party

Company: Autolus Therapeutics PLC Sponsored ADR

Industry: Medical - Biomedical and Genetics

Record: 26

01/31/2020

Company Report

Pages: 10

AUTO3-Differentiated Profile Manifesting in Safety

Provider: H.C. Wainwright & Co., Inc.

Analyst: CHATTOPADHYAY D

Price: 25.00

Research Provided by a Third Party

Company: Autolus Therapeutics PLC Sponsored ADR

Industry: Medical - Biomedical and Genetics

Record: 27

01/09/2020

Daily Note

Pages: 18

2020 Catalyst Calendar and Top Picks Across Mid, Small, and Micro Caps

Provider: H.C. Wainwright & Co., Inc.

Analyst: CHATTOPADHYAY D

Price: 50.00

Research Provided by a Third Party

Company: Autolus Therapeutics PLC Sponsored ADR

Industry: Medical - Biomedical and Genetics

Record: 28

12/09/2019

Daily Note

Pages: 4

AUTO1 in Adult ALL Continues to Shine, AUTO3 in DLBCL Is Potentially Better Served With NG-Modules

Provider: H.C. Wainwright & Co., Inc.

Analyst: CHATTOPADHYAY D

Price: 10.00

Research Provided by a Third Party

Company: Autolus Therapeutics PLC Sponsored ADR

Industry: Medical - Biomedical and Genetics

Record: 29

11/08/2019

Company Report

Pages: 9

Autolus 3Q19 Update; Awaiting Introduction of NG-Modules and AUTO4 Updates

Provider: H.C. Wainwright & Co., Inc.

Analyst: CHATTOPADHYAY D

Price: 25.00

Research Provided by a Third Party

Company: Autolus Therapeutics PLC Sponsored ADR

Industry: Medical - Biomedical and Genetics

Record: 30

11/07/2019

Daily Note

Pages: 4

AUTO1 Updates at ASH to Highlight Expansion Beyond Pediatric to Adult ALL

Provider: H.C. Wainwright & Co., Inc.

Analyst: CHATTOPADHYAY D

Price: 10.00

Research Provided by a Third Party

Company: Autolus Therapeutics PLC Sponsored ADR

Industry: Medical - Biomedical and Genetics

Record: 31

09/12/2019

Company Report

Pages: 10

Albatross Loosens its Grip; Time to Revisit the Pipeline

Provider: H.C. Wainwright & Co., Inc.

Analyst: CHATTOPADHYAY D

Price: 25.00

Research Provided by a Third Party

Company: Autolus Therapeutics PLC Sponsored ADR

Industry: Medical - Biomedical and Genetics

Record: 32

08/12/2019

Company Report

Pages: 10

Competitive Landscape Compels Pipeline Rationalization; Target Lowered to $24

Provider: H.C. Wainwright & Co., Inc.

Analyst: CHATTOPADHYAY D

Price: 25.00

Research Provided by a Third Party

Company: Autolus Therapeutics PLC Sponsored ADR

Industry: Medical - Biomedical and Genetics

Record: 33

06/24/2019

Industry Report

Pages: 19

Our Thoughts Post CAR-T and the Rise of the Cellicon Valley Summit

Provider: H.C. Wainwright & Co., Inc.

Analyst: CHATTOPADHYAY D

Price: 50.00

Research Provided by a Third Party

Company: Autolus Therapeutics PLC Sponsored ADR

Industry: Medical - Biomedical and Genetics

Record: 34

05/17/2019

Company Report

Pages: 9

1Q in the Rear View; Targeting Multiple Program Read Outs at ASH; Target Lowered to $41 Reflecting Recent Secondary

Provider: H.C. Wainwright & Co., Inc.

Analyst: CHATTOPADHYAY D

Price: 25.00

Research Provided by a Third Party

Company: Autolus Therapeutics PLC Sponsored ADR

Industry: Medical - Biomedical and Genetics

Record: 35

04/03/2019

Company Report

Pages: 9

Thoughts Post Preliminary AUTO1 Update in Adult ALL; More Than Viable With Registration Study to Commence During 2H19

Provider: H.C. Wainwright & Co., Inc.

Analyst: CHATTOPADHYAY D

Price: 25.00

Research Provided by a Third Party

Company: Autolus Therapeutics PLC Sponsored ADR

Industry: Medical - Biomedical and Genetics

Record: 36

04/01/2019

Company Report

Pages: 10

A Preamble Into Next Generations CAR T Modules

Provider: H.C. Wainwright & Co., Inc.

Analyst: CHATTOPADHYAY D

Price: 25.00

Research Provided by a Third Party

Company: Autolus Therapeutics PLC Sponsored ADR

Industry: Medical - Biomedical and Genetics

Record: 37

03/11/2019

Company Report

Pages: 11

An Eye Out for the March 26, 2019 R-D Day and the Undisclosed Next-gen CAR T Programs Likely to Be Unveiled Therein

Provider: H.C. Wainwright & Co., Inc.

Analyst: CHATTOPADHYAY D

Price: 25.00

Research Provided by a Third Party

Company: Autolus Therapeutics PLC Sponsored ADR

Industry: Medical - Biomedical and Genetics

Record: 38

02/20/2019

Company Report

Pages: 10

CARPALL Paves the Way for ALLCAR19; but It Is AMELIA That Intrigues Us

Provider: H.C. Wainwright & Co., Inc.

Analyst: CHATTOPADHYAY D

Price: 25.00

Research Provided by a Third Party

Company: Autolus Therapeutics PLC Sponsored ADR

Industry: Medical - Biomedical and Genetics

Record: 39

12/03/2018

Company Report

Pages: 10

AMELIA and ALEXANDER Clinical Updates; and Novel CAR T Targeting PTCL Enters the Clinic

Provider: H.C. Wainwright & Co., Inc.

Analyst: CHATTOPADHYAY D

Price: 25.00

Research Provided by a Third Party

Company: Autolus Therapeutics PLC Sponsored ADR

Industry: Medical - Biomedical and Genetics

Record: 40

11/02/2018

Company Report

Pages: 10

AUTO3, a CD19xCD22 CAR at ASH 2018; Preliminary Data Affirms Safety With no Antigen Negative Escape

Provider: H.C. Wainwright & Co., Inc.

Analyst: CHATTOPADHYAY D

Price: 25.00

Research Provided by a Third Party